CDMO
-
【Acquisition of Manufacturing Facilities】Seeking pharmaceutical/healthcare CMO/CDMO manufacturing facilities in the United States, Europe, United Kingdom, and Australia. Budget: USD 10 million
If your company is interested in this opportunity, please contact DrugTimes BD team as soon as possible!
-
【收购工厂】美国、欧洲、英国、澳大利亚药品/保健品CMO/CDMO工厂,预算1000万美元
如果贵公司对这个机会感兴趣,请速速联系药时代BD团队!
-
The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings
Novo Nordisk still expects the acquisition to be completed towards the end of 2024
-
【重磅消息】欧盟委员会无条件批准了Novo Holdings对Catalent的165亿美元收购计划
药时代将持续跟踪报道这一重要交易的进展,欢迎广大朋友们关注药时代,获取最新资讯!
-
8 Key Highlights! What Do Global Pharma Industry BD and M&A Trends Forecast for 2024?
Where Pharma is Investing for the Future of Medicine: Biopharma Deal Making in 2024
-
How Chinese CXOs Answer the Question of Going Global?
As Porton is about to celebrate its 19th anniversary, can this company once again accurately seize the opportunity and step into its 20th birthday with a brand-new posture? It is worth looking forward to
-
博腾药时代直播间 | 流体化学技术在制药CDMO应用的特色及案例分享
原文始发于微信公众号(药时代):博腾药时代直播间 | 流体化学技术在制药CDMO应用的特色及案例分享 流体化学是全球公认的颠覆传统药物研发和生产的绿色安全制药技术,为药物的合成路线…
-
国内工艺验证项目陆续引入,博腾中国NDA项目实现重要突破
近日,重庆博腾制药科技股份有公司(股票简称:博腾股份,股票代码:300363)中国市场业务开发捷报频传,多个中国Biotech客户的NDA (New Drug Applicatio…
-
博腾药时代直播间 | 流体化学技术在制药CDMO应用的特色及案例分享
流体化学是全球公认的颠覆传统药物研发和生产的绿色安全制药技术,为药物的合成路线设计提供了更多的灵活性和选择性,可以从合成工艺源头守护安全、提高效率、减少污染。其在反应过程中具有以下…
-
我和我的IND | 今晚7:30,全力助您新药研发夺冠!
原文始发于微信公众号(药时代):我和我的IND | 今晚7:30,全力助您新药研发夺冠! 新药研发是一项风险大,投入高,周期长的工作。一个创新药品从立项到最终成功上市,可能需要十余…